These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

112 related items for PubMed ID: 29929760

  • 1. Dignified blindness and age-related macular degeneration. A necessary multidisciplinary approach.
    Fernández-Vigo JÁ, Fernández-Vigo JI, Serrano Garijo P, Donate-López J.
    Arch Soc Esp Oftalmol (Engl Ed); 2018 Nov; 93(11):519-522. PubMed ID: 29929760
    [No Abstract] [Full Text] [Related]

  • 2. Time to ask patients about drugs for macular degeneration.
    Mackenzie JW.
    BMJ; 2017 Nov 28; 359():j5426. PubMed ID: 29184013
    [No Abstract] [Full Text] [Related]

  • 3. Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies.
    Carrasco J, Pietsch GA, Nicolas MP, Koerber C, Bennison C, Yoon J.
    Adv Ther; 2020 Jan 28; 37(1):300-315. PubMed ID: 31728825
    [Abstract] [Full Text] [Related]

  • 4. Is part of the ophthalmologist's role in age-related macular degeneration change management of a chronic disease?
    Jackson ML.
    Arch Ophthalmol; 2004 Jul 28; 122(7):1090; author reply 1090. PubMed ID: 15249394
    [No Abstract] [Full Text] [Related]

  • 5. Should Avastin be used to treat age-related macular degeneration in the NHS?--Yes.
    Raftery J, Dent L.
    Eye (Lond); 2009 Jun 28; 23(6):1247-9. PubMed ID: 19407834
    [No Abstract] [Full Text] [Related]

  • 6. Anti-vascular endothelial growth factor in neovascular age-related macular degeneration - a systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems.
    Finger RP, Daien V, Eldem BM, Talks JS, Korobelnik JF, Mitchell P, Sakamoto T, Wong TY, Pantiri K, Carrasco J.
    BMC Ophthalmol; 2020 Jul 17; 20(1):294. PubMed ID: 32680477
    [Abstract] [Full Text] [Related]

  • 7. Costs of treatment for age-related macular degeneration.
    Gerson JD.
    Optometry; 2009 Jul 17; 80(7):339. PubMed ID: 19753688
    [No Abstract] [Full Text] [Related]

  • 8. [Vision for patients with macular degeneration].
    Paukstadt W.
    MMW Fortschr Med; 2007 Jan 18; 149(3):10-2. PubMed ID: 17619375
    [No Abstract] [Full Text] [Related]

  • 9. [Age-related visual loss].
    Neubauer AS, Kernt M.
    MMW Fortschr Med; 2013 Feb 07; 155(2):36-7. PubMed ID: 23573743
    [No Abstract] [Full Text] [Related]

  • 10. [A new drug for macular degeneration. A breakthrough accomplished (interview by Waldtraud Paukstadt)].
    Holz FG.
    MMW Fortschr Med; 2007 Jan 18; 149(3):13-4. PubMed ID: 17619376
    [No Abstract] [Full Text] [Related]

  • 11. Position paper: the need for head-to-head studies comparing Avastin versus Lucentis.
    Schmucker C, Antes G, Lelgemann M.
    Surv Ophthalmol; 2009 Jan 18; 54(6):705-7. PubMed ID: 19818262
    [No Abstract] [Full Text] [Related]

  • 12. Implications of "not me" drugs for health systems: lessons from age related macular degeneration.
    Campbell RJ, Dhalla IA, Gill SS, Bell CM.
    BMJ; 2012 May 01; 344():e2941. PubMed ID: 22549055
    [No Abstract] [Full Text] [Related]

  • 13. Avastin is as effective as Lucentis for wet AMD and could save NHS 84m pound a year, study shows.
    Hawkes N.
    BMJ; 2012 May 09; 344():e3275. PubMed ID: 22573655
    [No Abstract] [Full Text] [Related]

  • 14. [New drug treatment for age-related macular degeneration].
    Stefánsson E, la Cour M, Helgadóttir G, Sigurdsson H, Jónasson F.
    Laeknabladid; 2007 Apr 09; 93(4):299-301. PubMed ID: 17460341
    [Abstract] [Full Text] [Related]

  • 15. New treatments for age-related macular degeneration.
    Wagle AM, Yeo TK, Au Eong KG.
    Lancet; 2007 Oct 27; 370(9597):1481. PubMed ID: 17964347
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Using contrast sensitivity to estimate the cost-effectiveness of verteporfin in patients with predominantly classic age-related macular degeneration.
    Bansback N, Davis S, Brazier J.
    Eye (Lond); 2007 Dec 27; 21(12):1455-63. PubMed ID: 17086167
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Age-Related Macular Degeneration (AMD) Agents.
    Insight; 2015 Dec 27; 40(3):22-4. PubMed ID: 26364500
    [No Abstract] [Full Text] [Related]

  • 20. Intravitreal Ranibizumab for the Treatment of Visual Impairment Due to Choroidal Neovascularization Associated with Rare Diseases: Cost-Effectiveness in the UK.
    McCarthy G, Fenu E, Bennett N, Almond C.
    Adv Ther; 2019 Mar 27; 36(3):632-644. PubMed ID: 30726549
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.